Goleva E, Covar R, Martin RJ, Leung DY
However, despite the anti-diabetic and anti-obesity functions, of these dual and triple agonists, the long-term safety, cardiovascular, and renal benefits of these multi-target therapies need further validation
This is related to an imbalance in reactive oxygen species (ROS) homeostasis, which is mainly regulated by mitochondrial function, thereby suggesting a link between oxidative impairment in mitochondrial function in response to chronic stress and mood instability (Lushchak et al., 2023)
These results were so impressive that tirzepatide earned its own place in weight management: as of late 2023, the FDA has also approved it under the name Zepbound specifically for chronic weight management in obesity (making it officially indicated for weight loss, not just diabetes)